The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer

BMC Cancer

Ivett Teleki¹  Tibor Krenacs⁵  Marcell A Szasz⁷  Janina Kulka⁷  Barna Wichmann²  Cornelia Leo³  Barbel Papassotiropoulos⁴  Cosima Riemenschnitter⁶  Holger Moch⁶  Zsuzsanna Varga⁶ 

[1] 1st Department of Pathology & Experimental Cancer Research, Semmelweis University, Budapest, Hungary

[2] 2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary

[3] Division of Gynecology, University Hospital Zurich, Zurich, Switzerland

[4] Breast Cancer Center Seefeld, Zurich, Switzerland

[5] MTA-SE Tumour Progression Research Group, Budapest, Hungary

[6] Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland

[7] 2nd Department of Pathology, Semmelweis University, Budapest, Hungary

关键词: Prognosis;    Preoperative chemotherapy;    Gap junction;    Connexin;    Breast cancer;   

Others  :  1079940
DOI  :  10.1186/1471-2407-13-50

 received in 2012-06-27, accepted in 2013-01-30,  发布年份 2013

【 摘 要 】

Background

Several classification systems are available to assess pathological response to neoadjuvant chemotherapy in breast cancer, but reliable biomarkers to predict the efficiency of primary systemic therapy (PST) are still missing. Deregulation of gap junction channel forming connexins (Cx) has been implicated in carcinogenesis and tumour progression through loss of cell cycle control. In this study we correlated Cx expression and cell proliferation with disease survival and pathological response to neoadjuvant chemotherapy in breast cancers using existing classification systems.

Methods

The expression of Cx26, Cx32, Cx43, Cx46 and Ki67 was evaluated in 96 breast cancer patients prior to and after neoadjuvant chemotherapy using duplicate cores in tissue microarrays (TMA). Cx plaques of <1μm were detected with multilayer, multichannel fluorescence digital microscopy. Current classifications to assess residual tumour burden after primary systemic therapy included the EWGBSP, CPS-EG, Miller-Payne, Sataloff and NSABP systems.

Results

In our cohort dominated by hormone receptor (ER/PR) positive and HER2 negative cases, only the CPS-EG classification showed prognostic relevance: cases with scores 1–2 had significantly better overall survival (p=0.015) than cases with scores 3–5. Pre-chemotherapy Cx43 expression correlated positively with hormone receptor status both before and after chemotherapy and had a negative correlation with HER2 expression pre-chemotherapy. There was a positive correlation between Cx32 and HER2 expression pre-chemotherapy and between Cx32 and Ki67 expression post-chemotherapy. A negative correlation was found between post-chemotherapy Cx46 and Ki67 expression. Decreased post-chemotherapy Cx26 expression (<5%) statistically correlated with better overall survival (p=0.011). Moderate or higher Cx46 expression (>20%) pre- and post-chemotherapy correlated with significantly better survival in the intermediate prognostic subgroups of EWGBSP TR2b (p_pre-chemo=0.006; Sataloff TB (p_pre-chemo=0.005; p_post-chemo=0.029) and in Miller-Payne G3 (p_pre-chemo=0.002; p_post-chemo=0.012) classifications. Pre-chemotherapy, Cx46 expression was the only marker that correlated with overall survival within these subgroups.

Conclusion

Our results suggest that Cx46 and Cx26 expression in breast cancer may improve the assessment of pathological response and refine intermediate prognostic subgroups of residual tumour classifications used after neoadjuvant chemotherapy.

【 授权许可】

   
2013 Teleki et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
• [2]Payne SJ, Bowen RL, Jones JL, Wells CA: Predictive markers in breast cancer–the present. Histopathology 2008, 52(1):82-90.
• [3]Cserni G, Francz M, Jaray B, Kalman E, Kovacs I, Kulka J, Orosz Z, Udvarhelyi N, Vass L: Pathologic diagnosis and histopathology record of breast cancer. Magy Onkol 2010, 54(3):217-226.
• [4]Kuroi K, Toi M, Tsuda H, Kurosumi M, Akiyama F: Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. Breast Cancer 2006, 13(1):38-48.
• [5]Mittendorf EA, Jeruss JS, Tucker SL, Kolli A, Newman LA, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, et al.: Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011, 29(15):1956-1962.
• [6]Sahoo S, Lester SC: Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Arch Pathol Lab Med 2009, 133(4):633-642.
• [7]Shien T, Shimizu C, Seki K, Shibata T, Hojo T, Ando M, Kohno T, Katsumata N, Akashi-Tanaka S, Kinoshita T, et al.: Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome. Breast Cancer Res Treat 2009, 113(2):307-313.
• [8]Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK: Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 2008, 26(2):246-252.
• [9]Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK: Staging of breast cancer in the neoadjuvant setting. Cancer Res 2008, 68(16):6477-6481.
• [10]Czyz J: The stage-specific function of gap junctions during tumourigenesis. Cell Mol Biol Lett 2008, 13(1):92-102.
• [11]Goodenough DA, Paul DL: Gap junctions. Cold Spring Harb Perspect Biol 2009, 1(1):a002576.
• [12]Vinken M, Vanhaecke T, Papeleu P, Snykers S, Henkens T, Rogiers V: Connexins and their channels in cell growth and cell death. Cell Signal 2006, 18(5):592-600.
• [13]Rackauskas M, Neverauskas V, Skeberdis VA: Diversity and properties of connexin gap junction channels. Medicina (Kaunas) 2010, 46(1):1-12.
• [14]Houghton FD: Role of gap junctions during early embryo development. Reproduction 2005, 129(2):129-135.
• [15]Krysko DV, Leybaert L, Vandenabeele P, D'Herde K: Gap junctions and the propagation of cell survival and cell death signals. Apoptosis 2005, 10(3):459-469.
• [16]Herve JC, Derangeon M, Sarrouilhe D, Giepmans BN, Bourmeyster N: Gap junctional channels are parts of multiprotein complexes. Biochim Biophys Acta 2012, 1818(8):1844-1865.
• [17]Locke D: Gap junctions in normal and neoplastic mammary gland. J Pathol 1998, 186(4):343-349.
• [18]Pointis G, Fiorini C, Gilleron J, Carette D, Segretain D: Connexins as precocious markers and molecular targets for chemical and pharmacological agents in carcinogenesis. Curr Med Chem 2007, 14(21):2288-2303.
• [19]Cronier L, Crespin S, Strale PO, Defamie N, Mesnil M: Gap junctions and cancer: new functions for an old story. Antioxid Redox Signal 2009, 11(2):323-338.
• [20]Oviedo-Orta E, Errington RJ, Evans WH: Gap junction intercellular communication during lymphocyte transendothelial migration. Cell Biol Int 2002, 26(3):253-263.
• [21]Kanczuga-Koda L, Sulkowska M, Koda M, Rutkowski R, Sulkowski S: Increased expression of gap junction protein–connexin 32 in lymph node metastases of human ductal breast cancer. Folia Histochem Cytobiol 2007, 45(Suppl 1):S175-S180.
• [22]Kanczuga-Koda L, Sulkowski S, Lenczewski A, Koda M, Wincewicz A, Baltaziak M, Sulkowska M: Increased expression of connexins 26 and 43 in lymph node metastases of breast cancer. J Clin Pathol 2006, 59(4):429-433.
• [23]McLachlan E, Shao Q, Laird DW: Connexins and gap junctions in mammary gland development and breast cancer progression. J Membr Biol 2007, 218(1–3):107-121.
• [24]Banerjee D, Gakhar G, Madgwick D, Hurt A, Takemoto D, Nguyen TA: A novel role of gap junction connexin46 protein to protect breast tumours from hypoxia. Int J Cancer 2010, 127(4):839-848.
• [25]Fattaneh A, Tavassoli PD: WHO Series, Tumours of the Breast and Female Genital Organs. 2003, 18-19.
• [26]Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25(1):118-145.
• [27]Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumour specimens. Nat Med 1998, 4(7):844-847.
• [28]Theurillat JP, Zurrer-Hardi U, Varga Z, Barghorn A, Saller E, Frei C, Storz M, Behnke S, Seifert B, Fehr M, et al.: Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterparts. Int J Cancer 2008, 122(7):1585-1591.
• [29]Sohl G, Willecke K: Gap junctions and the connexin protein family. Cardiovasc Res 2004, 62(2):228-232.
• [30]Krenacs T, Ficsor L, Varga SV, Angeli V, Molnar B: Digital microscopy for boosting database integration and analysis in TMA studies. Methods in molecular biology (Clifton, NJ) 2010, 664:163-175.
• [31]Miglietta L, Vanella P, Canobbio L, Naso C, Cerisola N, Meszaros P, Parodi MA, Morabito F: Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis. Oncology 2010, 79(3–4):255-261.
• [32]Kyo N, Yamamoto H, Takeda Y, Ezumi K, Ngan CY, Terayama M, Miyake M, Takemasa I, Ikeda M, Doki Y, et al.: Overexpression of connexin 26 in carcinoma of the pancreas. Oncol Rep 2008, 19(3):627-631.
• [33]Tate AW, Lung T, Radhakrishnan A, Lim SD, Lin X, Edlund M: Changes in gap junctional connexin isoforms during prostate cancer progression. Prostate 2006, 66(1):19-31.
• [34]Liu X, Furuya T, Li D, Xu J, Cao X, Li Q, Xu Z, Sasaki K: Connexin 26 expression correlates with less aggressive phenotype of intestinal type-gastric carcinomas. Int J Mol Med 2010, 25(5):709-716.
• [35]Nomura S, Maeda K, Noda E, Inoue T, Fukunaga S, Nagahara H, Hirakawa K: Clinical significance of the expression of connexin26 in colorectal cancer. J Exp Clin Cancer Res 2010, 29:79. BioMed Central Full Text
• [36]Bier A, Oviedo-Landaverde I, Zhao J, Mamane Y, Kandouz M, Batist G: Connexin43 pseudogene in breast cancer cells offers a novel therapeutic target. Mol Cancer Ther 2009, 8(4):786-793.
• [37]Kamei J, Toyofuku T, Hori M: Negative regulation of p21 by beta-catenin/TCF signaling: a novel mechanism by which cell adhesion molecules regulate cell proliferation. Biochem Biophys Res Commun 2003, 312(2):380-387.
• [38]Lee SW, Tomasetto C, Paul D, Keyomarsi K, Sager R: Transcriptional downregulation of gap-junction proteins blocks junctional communication in human mammary tumour cell lines. J Cell Biol 1992, 118(5):1213-1221.
• [39]Conklin C, Huntsman D, Yorida E, Makretsov N, Turbin D, Bechberger JF, Sin WC, Naus CC: Tissue microarray analysis of connexin expression and its prognostic significance in human breast cancer. Cancer Lett 2007, 255(2):284-294.
• [40]Kulka J, Tokes AM, Toth AI, Szasz AM, Farkas A, Borka K, Jaray B, Szekely E, Istok R, Lotz G, et al.: Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy. Magy Onkol 2009, 53(4):335-343.
• [41]Neubauer H, Gall C, Vogel U, Hornung R, Wallwiener D, Solomayer E, Fehm T: Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res 2008, 28(3B):1797-1804.
• [42]van de Ven S, Smit VT, Dekker TJ, Nortier JW, Kroep JR: Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev 2011, 37(6):422-430.
• [43]Varga Z, Caduff R, Pestalozzi B: Stability of the HER2 gene after primary chemotherapy in advanced breast cancer. Virchows Arch 2005, 446(2):136-141.
• [44]Darb-Esfahani S, Loibl S, Muller BM, Roller M, Denkert C, Komor M, Schluns K, Blohmer JU, Budczies J, Gerber B, et al.: Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res 2009, 11(5):R69. BioMed Central Full Text
• [45]Denkert C, Sinn BV, Issa Y, Maria Muller B, Maisch A, Untch M, von Minckwitz G, Loibl S: Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts. Breast Care (Basel) 2011, 6(4):265-272.
• [46]Guiu S, Gauthier M, Coudert B, Bonnetain F, Favier L, Ladoire S, Tixier H, Guiu B, Penault-Llorca F, Ettore F, et al.: Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer. Br J Cancer 2010, 103(9):1335-1342.
• [47]Precht LM, Lowe KA, Atwood M, Beatty JD: Neoadjuvant chemotherapy of breast cancer: tumour markers as predictors of pathologic response, recurrence, and survival. Breast J 2010, 16(4):362-368.
• [48]Untch M, Fasching PA, Konecny GE, Hasmuller S, Lebeau A, Kreienberg R, Camara O, Muller V, du Bois A, Kuhn T, et al.: Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 2011, 29(25):3351-3357.
• [49]von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, et al.: Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 2008, 10(2):R30. BioMed Central Full Text
• [50]Osako T, Horii R, Matsuura M, Ogiya A, Domoto K, Miyagi Y, Takahashi S, Ito Y, Iwase T, Akiyama F: Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy. J Cancer Res Clin Oncol 2010, 136(2):233-241.